Engene, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Sep 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Apr 29, 2027
- 1 fee due Nov 12, 2027The maintenance fee for High Concentration Chitosan-Nucleic Acid Polyplex Compositions (US 10,647,785) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,850,323 | High Concentration Chitosan-Nucleic Acid Polyplex Compositions In force · High confidence | In force | High confidence | |
| US 10,647,785 | High Concentration Chitosan-Nucleic Acid Polyplex Compositions In force · High confidence | In force | High confidence | |
| US 9,404,088 | Chitosan-based non-viral methods for transfecting gut cells in vivo In force · High confidence | In force | High confidence | |
| US 8,722,646 | High Concentration Chitosan-Nucleic Acid Polyplex Compositions In force · High confidence | In force | High confidence | |
| US 8,846,102 | Non-Viral Compositions and Methods for Transfecting Gut Cells in Vivo In force · High confidence | In force | High confidence | |
| US 10,456,478 | Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo In force · High confidence | In force | High confidence | |
| US 11,623,011 | Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo In force · High confidence | In force | High confidence | |
| US 9,623,112 | Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 10,456,481 | Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo In force · High confidence | In force | High confidence | |
| US 11,167,045 | Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 2 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 2 abandoned · 3 no status recorded
Showing 1 to 10 of 11, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/821,962 | Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo | Aug 30, 2024 | Pending |
| 18/125,651 | Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo | Mar 23, 2023 | Pending |
| 18/121,557 | Intestinal Expression of Programmed Death Ligand 1 | Mar 14, 2023 | Abandoned |
| 18/277,944 | Combination Gene Therapy for Treatment of Metastatic Cancer | Feb 18, 2022 | Pending |
| 17/794,577 | Localized Expression of Therapeutic Nucleic Acids in Lung Epithelial Cells | Jan 22, 2021 | Pending |
| 17/438,922 | Chitosan Polyplex-Based Localized Expression of IL-12 Alone or in Combination with Type-I Ifn Inducers for Treatment of Mucosal Cancers | Mar 13, 2020 | Pending |
| 17/438,921 | Reversible Coating of Chitosan-Nucleic Acid Nanoparticles and Methods of Their Use | Mar 13, 2020 | Pending |
| 13/175,750 | Compositions and Methods for Regulated Protein Expression in Gut | Jul 1, 2011 | Abandoned |
| 12/751,572 | Mar 31, 2010 | No status recorded | |
| 12/017,902 | Jan 22, 2008 | No status recorded |
10 of 11 applications shown.
Pro members see all 11 published applications.